Patents Assigned to Mochida Pharmaceutical Co., Ltd.
-
Publication number: 20210169837Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.Type: ApplicationFiled: February 19, 2021Publication date: June 10, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Masahiko OHTA, Shinichi OIKAWA, Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
-
Publication number: 20210128510Abstract: A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100 mass %, 70 to 90 mass % of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids, pharmaceutically acceptable salts thereof, and esters of the same, 0.5 to 6 mass % of water and 1 to 29 mass % of an emulsifying agent that comprises a polyoxyethylene sorbitan fatty acid ester (and that further contains a polyoxyl castor oil optionally, with the proviso that the emulsifying agent does not include lecithin) and which contains 3 to 40 parts by mass of lecithin relative to 100 parts by weight of the ?3 polyunsaturated fatty acid or the like. This self-emulsifying composition exhibits excellent self-emulsifying properties, composition dispersibility, emulsion stability and absorbability, and does not contain ethanol or a polyhydric alcohol or contains the same only in a low concentration. The self-emulsifying composition is useful for food and medicine.Type: ApplicationFiled: January 6, 2021Publication date: May 6, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
-
Publication number: 20210107990Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.Type: ApplicationFiled: May 1, 2020Publication date: April 15, 2021Applicant: Mochida Pharmaceutical Co., Ltd.Inventor: Kamon Shirakawa
-
Patent number: 10966929Abstract: The present invention provides: a freeze-dried composition which comprises (a) a monovalent metal alginate and (b) a salt selected from a monovalent metal salt and an ammonium salt; and a method of producing a freeze-dried monovalent metal alginate composition which comprises the steps of freezing an aqueous solution formed by dissolving at least the component (a) and the component (b), performing first drying, and then performing second drying as desired to reduce a water content to 3% by mass or less. This is a freeze-dried monovalent metal alginate composition with suppressed viscosity decrease with the lapse of time.Type: GrantFiled: September 6, 2016Date of Patent: April 6, 2021Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shuichi Endo, Naoya Yoshioka
-
Publication number: 20210095053Abstract: The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.Type: ApplicationFiled: December 11, 2020Publication date: April 1, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Tomohiro NARUMI, Tsutomu SATOH
-
Patent number: 10927079Abstract: An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)?(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.Type: GrantFiled: April 15, 2020Date of Patent: February 23, 2021Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventor: Yuji Kawada
-
Publication number: 20210024659Abstract: The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided.Type: ApplicationFiled: March 27, 2019Publication date: January 28, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Tsutomu SATOH, Tomohiro NARUMI
-
Publication number: 20210000968Abstract: Provided is water-soluble compound that can be used in a sustained-release preparation and is capable of stably releasing a fixed amount of an active ingredient in vivo by using the novel potential base material option of alginic acid as the base material.Type: ApplicationFiled: September 17, 2020Publication date: January 7, 2021Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Shoji FURUSAKO, Isao SAKURADA
-
Publication number: 20200397954Abstract: The purpose of the present invention is to provide an anti-adhesion material having a high anti-adhesion effect. The present invention pertains to an anti-adhesion material comprising a biocompatible sponge-like layered body having a sponge-like first layer and a sponge-like second layer both being at least partially crosslinked with a curing agent and comprising a low endotoxin monovalent metal salt of alginic acid. The monovalent metal salt of alginic acid in the first layer has a weight average molecular weight of 30000 to 300000. The monovalent metal salt of alginic acid in the second layer has a weight average molecular weight of 1000 to 200000. The weight average molecular weights are determined by GPC-MALS after a de-crosslinking treatment. The weight average molecular weight of the monovalent metal salt of alginic acid in the first layer is higher than the weight average molecular weight of the monovalent metal salt of alginic acid in the second layer.Type: ApplicationFiled: January 15, 2018Publication date: December 24, 2020Applicants: Mochida Pharmaceutical Co., Ltd., The University of TokyoInventors: Taichi ITO, Seiichi OHTA, Kiyoshi HASEGAWA, Mitsuko ISAJI, Satoshi SHIMIZU, Daichi TANAKA
-
Publication number: 20200390893Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.Type: ApplicationFiled: August 24, 2020Publication date: December 17, 2020Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA, Daichi TANAKA
-
Patent number: 10864185Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.Type: GrantFiled: January 22, 2020Date of Patent: December 15, 2020Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
-
Patent number: 10852302Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.Type: GrantFiled: September 7, 2016Date of Patent: December 1, 2020Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventor: Katsuki Naito
-
Publication number: 20200345852Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.Type: ApplicationFiled: July 17, 2020Publication date: November 5, 2020Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hiromitsu ITO, Hirosato FUJII, Motoo YAMAGATA
-
Publication number: 20200308136Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.Type: ApplicationFiled: September 13, 2018Publication date: October 1, 2020Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE, Tsutomu SATOH
-
Patent number: 10786575Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.Type: GrantFiled: February 11, 2019Date of Patent: September 29, 2020Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata, Daichi Tanaka
-
Publication number: 20200289547Abstract: The present invention provides a composition for filling the nucleus pulposus of an intervertebral disc, the composition containing a low endotoxin monovalent metal salt of alginic acid. The composition is applied to a nucleus pulposus site of a subject, is used so as to be cured partially after application, and has fluidity when applied to the nucleus pulposus site. Accordingly, a composition for filling nucleus pulposus is provided, the composition being capable of promoting the regeneration of the nucleus pulposus of an intervertebral disc.Type: ApplicationFiled: January 27, 2017Publication date: September 17, 2020Applicants: National University Corporation Hokkaido University, Mochida Pharmaceutical Co., LtdInventors: Hideki SUDO, Takeru TSUJIMOTO, Norimasa IWASAKI, Satoshi SHIMIZU, Mitsuko ISAJI
-
Patent number: 10758622Abstract: A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ?3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.Type: GrantFiled: January 21, 2015Date of Patent: September 1, 2020Assignee: MOCHIDA PHARMACEUTICALS CO., LTD.Inventors: Hiromitsu Ito, Hirosato Fujii, Motoo Yamagata
-
Publication number: 20200268931Abstract: Provided is a non-tubular brain damage recovery material which is used to cover and/or fill a damaged part of the brain, the brain damage recovery material including: (A) a cross-linked body with which a bioabsorbable polysaccharide having a carboxyl group in a low endotoxin molecule is covalently bonded and cross-linked with at least one crosslinking reagent selected from among a compound represented by general formula (I) and salts thereof; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [in the formula, R1 and R2 each independently represent a hydrogen atom or a group represented by formula of —COCH(NH2)—CH2]4—NH2, and n represents an integer from 2 to 18]. Accordingly, provided is a medical material which can recover a damaged part of the brain.Type: ApplicationFiled: September 13, 2017Publication date: August 27, 2020Applicants: Tazuke Kofukai, Mochida Pharmaceutical Co., Ltd.Inventors: Yoshihisa Suzuki, Masao TANIHARA, Mitsuko ISAJI
-
Publication number: 20200246299Abstract: Novel compositions comprising omega-3 fatty acids and uses thereof are disclosed.Type: ApplicationFiled: April 20, 2020Publication date: August 6, 2020Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Omar Abdelfattah ABU-BAKER, Donald MACKENZIE, Rennan PAN
-
Publication number: 20200239419Abstract: An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)?(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.Type: ApplicationFiled: April 15, 2020Publication date: July 30, 2020Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE